Pulmocide
London, United Kingdom · Founded 2013 · $201.4M raised
- Headquarters
- London
- Employees
- 11–50
- Founded
- 2013
- Business Model
- B2B
- Website
- pulmocide.com
- Total Funding
- $201.4M
- Last Round
- $30.4M Series BDec 2022
- Rounds
- 4
About
Biotech developing inhaled antifungal therapies for pulmonary aspergillosis and respiratory diseases.
Summary
Pulmocide is a Biotech company based in London, United Kingdom, founded in 2013. It has raised $201.4M in total across 4 rounds, most recently a $30.4M Series B round in Dec 2022. Investors include F-Prime Capital.
Tech & App Stack
4 technologies & apps tracked
Create a free account — 10 credits a month to unlock the full tech & app stack, funding history, and valuations.
Sign up to view the funding chart
Create a free account — you'll get 10 credits a month to unlock funding history, valuations, and tech stacks.
Funding History
Dec 2022
Sign up to see all 4 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Specialty pharmaceutical company
Biopharmaceutical services company
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...